Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Active, not recruiting · NCT04551430 · Registry updated 2025-11-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2025-11-12 | NCT04551430 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Exelixis | 77 |
| Washington University School of Medicine | 475 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Abramson Cancer Center at Pennsylvania Hospital | Philadelphia | United States | 3 |
| Stanford University Medical Center | Stanford | United States | 43 |
| University of Colorado | Aurora | United States | 147 |
| Washington University School of Medicine | St Louis | United States | 895 |